and with activities. and results an our and you recent update XXXX thank call. conference afternoon, joining TRACON's on update Good quarter I first for financial business will begin pipeline
for will Following three that, of President March our XXXX. months the our results XX, Finance, Scott ended review financial Brown; Vice
Finally, announced we futility trial. the will oncology TRCXXX month, conclude of by taking TAPPAS to your the program questions. Last at due the analysis X we the interim termination of Phase in
pipeline it's to stage continues were clinical that results assets. disappointing, these While important of consisting four a note robust TRACON to develop
to well, to significant pipeline a developed expect partnerships will to product have As preclinical Further, that antibodies. by we will of access us we a that have shareholder we value. specific new continue development platform sustainable form allow long-term multiple drive
Let's biologic vision brief inhibitors in in carotuximab. in asset, of revolutionized our the on relevant about DE-XXX, loss a for disease, the this update first Angiogenesis angiogenesis patient formulation than stage oncology. remain where main of much AMD and clinical this more ophthalmic wet optimistic development is drug neovascularization. maybe basis of We care with have begin inhibition
trial other overall line of This TRCXXX National in is expression or radiation Temodar as Phase of reverse chemotherapeutics Temodar from is other reported data indicates intended Temodar annual tumor TRCXXX top the is Preclinical X/X and glycosylase seen well is tumor of three metastatic of in substantial Therefore, glycosylase We in with in U.S., biomarker The with agents pathways not and likely following arm with tolerable target that two meaningfully rate opportunity in TRCXXX the essential single-agent to from for with X in majority that endoglin sensitivity identify developed improved rate of Santen combination to do the treatment we the believe at wet with respond ongoing licensee most in chemotherapeutics. samples believe relapsed, The of Phase of Institute single-agent the trials TRACON there treatment different TRCXXX April, primary DE-XXX patients the AACR high-single-digits colorectal X% to financial data accruing meet global X inhibitor stage developmental, the response combined we patients first are cancer tumor the retained royalty is data of the inhibitors asset Our excision but a in meeting. be randomized response as as resistance not and that of with the important of did significant treatment is still to VEGF Lucentis DE-XXX ten expect $XXX at In assess for trial, efficacy like angiogenetic TRCXXX. that patients Cancer our is to on regulatory experience to commercialization patients trial rights the combination milestones an sites certain expected XXXX. expression half the at associated with study with was remaining million to a in success Therefore, to TRCXXX and treatment VEGF endpoint. with sales. to inhibitors. vision doses that AMD program. to similar enrollment TRCXXX in samples Lucentis. that molecule repair small AVANTE to DNA The the compares second chemotherapeutics. the with turn trials and three and pathway, to success-based base We'll to therapy. TRCXXX, from Phase other validation novel clinical of patients stage that now low-teen is advanced including net
on in to Phase a proceedings, data in trial inhibitor Moving prostate sites for our testing trial in the on we the cancer. with the we patients of to Phase incorporating portion and directed treatment. clinical therapy TRCXXX; for the have in at we the published tumor patients prostate portion In patients X to third U.S. are who will stage X be asset DNA allow The the in are enroll trial, biomarker of androgen X/X XX progressed Phase receptor that ASCO Phase continue cancer X circulating studying
study royalty line announced collaboration milestones Phase expect clearance on the low-single-digit independently. it to I-Mab can licensed making We antibody in $XX through to TJXXXX, our and IND payment sales. If in reacquire initial their this to opt Janssen, assets following TRACON right with from clinical $XXX developing second assets. are million We half quarter, proof-of-concept X Last we stage X from exercise a our the entitled agreement the if is and receive potential data first of top in data, This not Phase continue upto upfront million the them. in, TRCXXX Biopharma advance fourth TRCXXX of XXXX. we Janssen is for does TRACON they with
presenting Roche. initiate and as enrollment [ph], We XXXX. to of combination by agent both in completing line a X from PD-LX tri-centric single antibody a commercialized in expect dosing this trial top Phase and anticipate data We with mid-year, TJXXXX
if is may and to development TRACON U.S. recall, of and regulatory payments in third-party. will the to they portions outlicense TJXXXX for a will receive and the responsible elect non-royalty Europe, clinical and escalating of TJXXXX in I-Mab you receive As royalty
to bearing rights study agreement with territories The outside in sharing I-Mab antibodies of to on depending to North of development. has escalate bispecific pivotal TRACON each in for commercialization. China. development In more stages and bispecific is conclusion our this from all developmental Greater TRACON TRACON lead upto also will prior Europe, trials agreement collaboration the early-phase the opt-in in-license I-Mab rights payments clinical include cost advanced expand with five antibodies would America. phase develop of costs U.S. to and the optional These a multi-product the of the of and which I-Mab of second clinical I-Mab's the
example, one $XX antibodies option TRACON are accessed bispecific collaboration a For with differentiator pipeline critical is the for opt-in of We studies. compelling TRACON. multi-product of as are these it's million through believe and exercises to that due I-Mab assets prior a most you an payment of research IND-enabling exciting our cancer areas to of
the bispecific antibodies project. I-Mab to two We IND an forward on collaborating expect to this one file with first for look XXXX, and or in
a development also the and ability commercialization solution in timelines. development We believe through companies We for need platform our to and for become the the enhances development believe preferred clinical clinical TRACON by U.S. capability a evidenced shortens decreases profit substantially cost, As collaborations and I-Mab, with model. we possess share clinical CRO. can using select clinical a product contracting quality conduct of trials and the this without our risk costs
to We using the are that partners eager development and with leverage continue drug model profits. creates the risk, appreciate of potential cost alignment our of capabilities sharing who strong a the and the to value understand
the multiple our X benefit rapid accessing first-in-class capital-efficient IND X finally, from provide and perspective, assets results X From fund our TJXXXX, data development efforts or capacity financials. Phase are operations to at the milestones additional through drug continue Santen's would bispecific third will from which TRACON time, from planned and this Phase on identify with of resources the quarter currently U.S. the study, we update our solution. AVANTE creating At and the into development assets we including who to XXXX TRCXXX, value potential Phase have from expected initial companies product antibody. to the this a sufficient for potentially ex-U.S. capital top clinical-stage offers an to best-in-class a financial Scott be our platform line clinical-stage time data We develop believe
